# A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis

> **NCT06104683** · PHASE2 · WITHDRAWN · sponsor: **Loxo Oncology, Inc.**

## Conditions studied

- Relapsing Multiple Sclerosis
- Multiple Sclerosis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Pirtobrutinib

## Key facts

- **NCT ID:** NCT06104683
- **Lead sponsor:** Loxo Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-05-01
- **Primary completion:** 2026-01-16
- **Final completion:** 2026-02-13
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor Decision: The trial has been withdrawn with no plans to continue development.
- **Last updated:** 2024-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06104683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06104683, "A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06104683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*